Commercial Insight - Epilepsy - Companies committed to the cause will reap the benefits
Commercial Insight - Epilepsy - Companies committed to the cause will reap the benefits - New Research Report on Companies and Markets
© companiesandmarkets.com
17.11.2008 18:04:01 www.companiesandmarkets.com adds new report - Commercial Insight - Epilepsy - Companies committed to the cause will reap the benefits
(live-PR.com) - www.companiesandmarkets.com/Summary-Market-Repor ..
Introduction
The current epilepsy market boasts a wide range of treatment options and has recently reached a state of maturity. The market value across the 7MM grew by just 2.3% from 2005 to $3.2 billion in 2006. However, imminent change to the market in the near to mid term will be brought about by the occurrence of key patent expiries and
new drugs launches.
Scope
This report focuses on drugs used to treat epilepsy, with indication- and country-specific sales value and volume forecasts to 2016. Assessment of current and future opportunities and threats in the epilepsy market across the 7MMs and in individual regions. Identification of future market events expected to impact epilepsy-specific anticonvulsant drug revenues over the next decade. Case study analysis of successful lifecycle management strategies and provision of key recommendations to ensure revenue growth.
Highlights
Despite advances in epilepsy treatment over the past 15 years, the efficacy of current anticonvulsants remains limited, with approximately 2030% of patients continuing to suffer from refractory seizures. As such, in an increasingly crowded market, targeting refractory epilepsy patients continues to present a potentially lucrative opportunity. Focusing on epilepsy rather than diversifying into other secondary CNS indications has played a pivotal role for UCB in ensuring Keppra´s market leadership and ongoing strong uptake. Demonstrating a solid commitment to the disease will be viewed favorably by neurologists and will promote brand loyalty. This, in turn will provide long-term growth. Keppra´s pediatric epilepsy indication expansions over the past 2 years have served to expand its patient base. In view of the high prevalence of childhood epilepsy and high level of unmet need in this patient group, gaining approval in the pediatric population remains an attractive means of increasing revenue and strengthening brand loyalty.
Reasons to Purchase
Quantify the future size of the epilepsy market, in terms of prescription volume and value, in each of the seven major markets. Assess the impact of future events such as patent expiries, indication expansions, and new product launches on the sales of key marketed brands. Identify key lifecycle management strategies and market opportunities that can ensure growth in the increasingly competitive epilepsy market.
Introduction
The current epilepsy market boasts a wide range of treatment options and has recently reached a state of maturity. The market value across the 7MM grew by just 2.3% from 2005 to $3.2 billion in 2006. However, imminent change to the market in the near to mid term will be brought about by the occurrence of key patent expiries and
|
|
Scope
This report focuses on drugs used to treat epilepsy, with indication- and country-specific sales value and volume forecasts to 2016. Assessment of current and future opportunities and threats in the epilepsy market across the 7MMs and in individual regions. Identification of future market events expected to impact epilepsy-specific anticonvulsant drug revenues over the next decade. Case study analysis of successful lifecycle management strategies and provision of key recommendations to ensure revenue growth.
Highlights
Despite advances in epilepsy treatment over the past 15 years, the efficacy of current anticonvulsants remains limited, with approximately 2030% of patients continuing to suffer from refractory seizures. As such, in an increasingly crowded market, targeting refractory epilepsy patients continues to present a potentially lucrative opportunity. Focusing on epilepsy rather than diversifying into other secondary CNS indications has played a pivotal role for UCB in ensuring Keppra´s market leadership and ongoing strong uptake. Demonstrating a solid commitment to the disease will be viewed favorably by neurologists and will promote brand loyalty. This, in turn will provide long-term growth. Keppra´s pediatric epilepsy indication expansions over the past 2 years have served to expand its patient base. In view of the high prevalence of childhood epilepsy and high level of unmet need in this patient group, gaining approval in the pediatric population remains an attractive means of increasing revenue and strengthening brand loyalty.
Reasons to Purchase
Quantify the future size of the epilepsy market, in terms of prescription volume and value, in each of the seven major markets. Assess the impact of future events such as patent expiries, indication expansions, and new product launches on the sales of key marketed brands. Identify key lifecycle management strategies and market opportunities that can ensure growth in the increasingly competitive epilepsy market.
| Author: |
